Skip to main
ALXO
ALXO logo

ALXO Stock Forecast & Price Target

ALXO Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

ALX Oncology Holdings Inc exhibits a promising financial outlook, with projected initial revenue of $45 million in 2032, escalating to $278 million by 2034. The company has successfully extended its cash runway into the fourth quarter of 2026, facilitating focused development on its breast and colorectal cancer programs, where the mechanism of action for the lead candidate, evorpacept, has been clinically de-risked. This strategic positioning not only enhances operational efficiency but also underscores the potential for significant revenue growth as the clinical trials advance.

Bears say

ALX Oncology Holdings reported no revenues for 1Q25, aligning with consensus estimates, but posted a higher net loss of $0.58 per share, exceeding the anticipated net loss of $0.47 per share. The company has also made the strategic decision to discontinue the evaluation of its product candidate, Evo, in head and neck squamous cell carcinoma (HNSCC) and bladder cancer due to underwhelming clinical data results. Furthermore, the FDA's request for a Phase 3 study using Enhertu as a control, citing insufficient data from the Phase 2 ASPEN-06 study for accelerated approval, raises concerns about the viability of ALX’s leading product candidate and its future revenue potential.

ALXO has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ALX Onconology Holdings Inc (ALXO) Forecast

Analysts have given ALXO a Buy based on their latest research and market trends.

According to 5 analysts, ALXO has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ALX Onconology Holdings Inc (ALXO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.